A prospective clinical Study to evaluate the Safety and Efficacy of two different 0.1% Riboflavin used in Corneal Cross-linking treatment for patients with Keratoconus

BIOTECH HEALTHCARE PVT LTD0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1.Unilateral/bilateral
•2.A diagnosis of keratoconus.
•3.Progressing keratoconus.
•4.Patients with Keratometric readings <= 55 D
•5.Patients >= 18 years of age
•6.Patients with clear central cornea, without apical scarring.
•7.Patients with corneal thickness >= 400 microns at the thinnest point.
•8.Patient willing to participate and sign informed consent
•9.Patient willing to come for all post-operative follow-up procedures as defined in study protocol.

•1.Eyes classified as either normal, atypical normal (except corneal ectasia), or keratoconus suspect on the severity grading scheme.
•2.A history of previous corneal surgery or the insertion of intrastromal ring implantation in the eye(s) to be treated.
•3.Previous corneal or Intraocular surgery
•4.Pellucid marginal corneal degeneration
•5.Eyes which are aphakic or pseudophakic and do not have a UV blocking lens implanted.
•6.A history of delayed epithelial healing.
•7.Patients with nystagmus or any other condition that would have prevented a steady gaze during the CXL treatment or other diagnostic tests.
•8.Pregnancy & Lactation
•9.Concurrent participation in another drug or device Study.

发起方

BIOTECH HEALTHCARE PVT LTD